Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.

Haematologica - 1 May 2021

Ross David M, Babon Jeffrey J, Tvorogov Denis, Thomas Daniel

Abstract excerpt

Activation of JAK-STAT signaling is one of the hallmarks of myelofibrosis, a myeloproliferative neoplasm that leads to inflammation, progressive bone marrow failure, and a risk of leukemic transformation. Around 90% of patients with myelofibrosis have a mutation in JAK2, MPL, or CALR: so-called 'driver' mutations that lead to activation of JAK2. Ruxolitinib, and other JAK2 inhibitors in clinical use, provide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biology
Share to Janus Kinase 2
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Share to Nitriles

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 33472356
DOI: 10.3324/haematol.2020.262691
PMCID: PMC8094080

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.PMID 33472356Read ↗

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.Semantic proximity Read ↗

The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.Semantic proximity Read ↗

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?Semantic proximity Read ↗

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disordersSemantic proximity Read ↗

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Semantic proximity Read ↗

How many JAK inhibitors in myelofibrosis?Semantic proximity Read ↗

Practical management of myelofibrosis with ruxolitinib.Semantic proximity Read ↗

The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.Semantic proximity Read ↗

Immunological Consequences of JAK Inhibition: Friend or Foe?Semantic proximity Read ↗

Use of <scp>JAK</scp> inhibitors in the management of myelofibrosis: a revision of the <scp>B</scp>ritish <scp>C</scp>ommittee for <scp>S</scp>tandards in <scp>H</scp>aematology <scp>G</scp>uidelines for <scp>I</scp>nvestigation and <scp>M</scp>anagement of <scp>M</scp>yelofibrosis 2012Semantic proximity Read ↗

Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.